136 related articles for article (PubMed ID: 21235090)
1. [Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].
Ito Y
Gan To Kagaku Ryoho; 2010 Dec; 37(13):2845-9. PubMed ID: 21235090
[No Abstract] [Full Text] [Related]
2. HER2 targeted therapy in breast cancer...beyond Herceptin.
Pal SK; Pegram M
Rev Endocr Metab Disord; 2007 Sep; 8(3):269-77. PubMed ID: 17899385
[TBL] [Abstract][Full Text] [Related]
3. Advances in HER2-positive breast cancer.
Sledge GW
Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
[No Abstract] [Full Text] [Related]
4. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
5. [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Yamashita T; Iwata K
Gan To Kagaku Ryoho; 2009 Dec; 36(13):2551-4. PubMed ID: 20104676
[No Abstract] [Full Text] [Related]
6. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
7. Information for patients. I have HER2 positive metastatic breast cancer: is my treatment working?
Oncology (Williston Park); 2009 Oct; 23(11 Suppl Nurse Ed):48a-48b. PubMed ID: 19856610
[No Abstract] [Full Text] [Related]
8. Information for patients. HER2: what you need to know.
Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
[No Abstract] [Full Text] [Related]
9. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
10. HER2 as a cancer stem-cell target.
Roesler R; Cornelio DB; Abujamra AL; Schwartsmann G
Lancet Oncol; 2010 Mar; 11(3):225-6. PubMed ID: 20202610
[No Abstract] [Full Text] [Related]
11. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
13. Personalised cancer management: closer, but not here yet.
Piccart M
Ann Oncol; 2013 Aug; 24(8):1951-5. PubMed ID: 23878113
[No Abstract] [Full Text] [Related]
14. Managing trastuzumab-resistant breast cancer.
Krop I
Clin Adv Hematol Oncol; 2009 Feb; 7(2):108-10. PubMed ID: 19367251
[No Abstract] [Full Text] [Related]
15. Antibodies as molecular target-based therapy: trastuzumab.
Tokuda Y
Int J Clin Oncol; 2003 Aug; 8(4):224-9. PubMed ID: 12955577
[TBL] [Abstract][Full Text] [Related]
16. ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
Clin Adv Hematol Oncol; 2003 Apr; 1(4):237. PubMed ID: 16224413
[No Abstract] [Full Text] [Related]
17. [Novel targeting therapy concept for breast cancer treatment].
Toi M
Nihon Yakurigaku Zasshi; 2008 Sep; 132(3):177-9. PubMed ID: 18787301
[No Abstract] [Full Text] [Related]
18. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer.
Morris SR; Carey LA
Oncology (Williston Park); 2006 Dec; 20(14):1763-71; discussion 1771-2, 1774-6. PubMed ID: 17263127
[TBL] [Abstract][Full Text] [Related]
20. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
[Next] [New Search]